Federica Pisaneschi

Dr. Federica Pisaneschi

Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2016 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
PLPaul G Leonard
Paul G Leonard
NSNikunj Satani
Nikunj Satani
DMDavid Maxwell
David Maxwell
YLYu-Hsi Lin
Yu-Hsi Lin
NHNaima Hammoudi
Naima Hammoudi
Florian MullerFlorian Muller
Florian Muller
SF2312, a phosphonate antibiotic, directly binds and inhibits the activity of the glycolytic enzyme enolase and is selectively toxic to ENO1-deleted glioma cells through inhibition of glycolysis and depletion of ATP. Despite being crucial for energy generation in most forms of life, few if any microbial antibiotics specifically inhibit glycolysis. To develop a specific inhibitor of the glycolytic enzyme enolase 2 (ENO2) for the treatment of cancers with deletion of ENO1 (encoding enolase 1), we modeled the synthetic tool compound inhibitor phosphonoacetohydroxamate (PhAH) into the active site of human ENO2. A ring-stabilized analog of PhAH, in which the hydroxamic nitrogen is linked to Cα by an ethylene bridge, was predicted to increase binding affinity by stabilizing the inhibitor in a bound conformation. Unexpectedly, a structure-based search revealed that our hypothesized backbone-stabilized PhAH bears strong similarity to SF2312, a phosphonate antibiotic of unknown mode of action produced by the actinomycete Micromonospora, which is active under anaerobic conditions. Here, we present multiple lines of evidence, including a novel X-ray structure, that SF2312 is a highly potent, low-nanomolar inhibitor of enolase.

23 November 2020 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
YLYu-Hsi Lin
Yu-Hsi Lin
NSNikunj Satani
Nikunj Satani
NHNaima Hammoudi
Naima Hammoudi
VYVictoria C. Yan
Victoria C. Yan
YBYasaman Barekatain
Yasaman Barekatain
Florian MullerFlorian Muller
Florian Muller

1 November 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YGY.N. Vashisht Gopal
Y.N. Vashisht Gopal
SGSeth Gammon
Seth Gammon
RPRishika Prasad
Rishika Prasad
BKBarbara Knighton
Barbara Knighton
FPFederica Pisaneschi
Federica Pisaneschi
MDMichael A Davies
Michael A Davies
Purpose: To determine if inhibition of mitochondrial oxidative phosphorylation (OxPhos) is an effective strategy against MAPK pathway inhibitor (MAPKi)-resistant BRAF-mutant melanomas. Experimental Design: The anti-melanoma activity of IACS-010759 (OPi), a novel OxPhos complex I inhibitor, was evaluated in vitro and in vivo. Mechanistic studies and predictors of response were evaluated using molecularly and metabolically stratified melanoma cell lines. 13C-labeling and targeted metabolomics were used to evaluate the effect of OPi on cellular energy utilization. OxPhos inhibition in vivo was evaluated non-invasively by [18F]-FAZA PET imaging. Results: OPi potently inhibited OxPhos and the in vivo growth of multiple MAPKi-resistant BRAF-mutant melanoma models with high OxPhos at well-tolerated doses. In vivo tumor regression with single agent OPi treatment correlated with inhibition of both MAPK and mTOR complex I activity. Unexpectedly, anti-tumor activity was not improved by combined treatment with MAPKi in vitro or in vivo. Signaling and growth inhibitory effects were mediated by LKB1-AMPK axis, and proportional to AMPK activation. OPi increased glucose incorporation into glycolysis, inhibited glucose and glutamine incorporation into the mitochondrial TCA cycle, and decreased cellular nucleotide and amino acid pools. Early changes in [18F]-FAZA PET uptake in vivo, and the degree of mTORC1 pathway inhibition in vitro, correlated with efficacy. Conclusions: Targeting OxPhos with OPi has significant anti-tumor activity in MAPKi-resistant, BRAF-mutant melanomas, and merits further clinical investigation as a potential new strategy to overcome intrinsic and acquired resistance to MAPKi in patients.

3 August 2000 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
FCFranca Maria Cordero
Franca Maria Cordero
FPFederica Pisaneschi
Federica Pisaneschi
Andrea GotiAndrea Goti
Andrea Goti
JOJean Ollivier
Jean Ollivier
JSJacques Salaün
Jacques Salaün
ABAlberto Brandi
Alberto Brandi

1 June 2002 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
FCFranca Maria Cordero
Franca Maria Cordero
FPFederica Pisaneschi
Federica Pisaneschi
MGMartina Gensini
Martina Gensini
Andrea GotiAndrea Goti
Andrea Goti
ABAlberto Brandi
Alberto Brandi

1 September 2010 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Open access
FPFederica Pisaneschi
Federica Pisaneschi
QNQuang-De Nguyen
Quang-De Nguyen
ESElham Shamsaei
Elham Shamsaei
MGMatthias Glaser
Matthias Glaser
Edward G. RobinsEdward G. Robins
Edward G. Robins
EAEric Ofori Aboagye
Eric Ofori Aboagye
The epidermal growth factor receptor (EGFR/c-ErbB1/HER1) is overexpressed in many cancers including breast, ovarian, endometrial, and non-small cell lung cancer. An EGFR specific imaging agent could facilitate clinical evaluation of primary tumors and/or metastases. To achieve this goal we designed and synthesized a small array of fluorine containing compounds based on a 3-cyanoquinoline core. A lead compound, 16, incorporating 2'-fluoroethyl-1,2,3-triazole was selected for evaluation as a radioligand based on its high affinity for EGFR kinase (IC50=1.81+/-0.18 nM), good cellular potency (IC50=21.97+/-9.06 nM), low lipophilicity and good metabolic stability. 'Click' labeling afforded [18F]16 in 37.0+/-3.6% decay corrected radiochemical yield based on azide [18F]14 and 7% end of synthesis (EOS) yield from aqueous fluoride. Compound [18F]16 was obtained with >99% radiochemical purity in a total synthesis time of 3 h. The compound showed good stability in vivo and a fourfold higher uptake in high EGFR expressing A431 tumor xenografts compared to low EGFR expressing HCT116 tumor xenografts. Furthermore, the radiotracer could be visualized in A431 tumor bearing mice by small animal PET imaging. Compound [18F]16 therefore constitutes a promising radiotracer for further evaluation for imaging of EGFR status.